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Syndromic panels for infectious disease have been suggested to be of value in point 47 
of care diagnostics for developing countries and for biodefense. To test the 48 
performance of isothermal Recombinase Polymerase Amplification (RPA) assays we 49 
developed a panel of ten RPAs for biothreat agents. The panel included RPA assays 50 
for Francisella tularensis, Yersinia pestis, Bacillus anthracis, variola virus, and 51 
Recerse Transcriptase Recombinase Polymerase Amplification (RT-RPA) assays for 52 
Rift Valley fever virus, Ebola virus, Sudan virus and Marburg virus. Their analytical 53 
sensitivities ranged from 16-21 molecules detected (probit analysis) for the majority 54 
of RPA and RT-RPA assays. A magnetic bead based total nucleic acid extraction 55 
method was combined with the RPA assays and tested using inactivated whole 56 
organisms spiked into plasma. The RPA showed comparable sensitivities to real time 57 
RCR assays in these extracts. 58 
The run times of the assays at 42°C ranged from 6-10 minutes and they showed no 59 
cross detection of any of target genomes of the panel nor of the human genome. The 60 
RPA assays therefore seem suitable for implementation of syndromic panels onto 61 




Syndromic panels for infectious and emerging infectious diseases have been 65 
suggested to be of value in point-of-care (POC) diagnostics for developing countries 66 
and for biodefense (29). Since the introduction of molecular diagnostics and in 67 
particular real time PCR, ample proof of its sensitivity and specificity has been 68 
generated. Indeed molecular diagnostics are deemed superior to bacterial culture 69 
techniques or serological diagnostics (6, 34, 44). It has even been suggested to 70 
entirely eliminate the old methods in order to streamline centralised laboratories for 71 
molecular diagnostics (5, 13, 14). 72 
In recent years alternative isothermal amplification methods which can be 73 
categorized into (i) T7 promotor driven amplifications (transcription mediated 74 
amplification (TMA), Nucleic Acid Sequence-Based Amplification (NASBA), Single 75 
primer isothermal amplification (SPIA)), (ii) strand displacement methods (Strand 76 
Displacement Amplification (SDA), Loop-mediated isothermal amplification (LAMP), 77 
Smart amplification (SmartAmp)), (iii) helicase dependent amplification (HDA), (iv) 78 
recombinase polymerase amplification (RPA), and (v) rolling circle amplification 79 
(RCA) methods (1, 3, 12, 17, 36) have been developed. Some were purposely 80 
designed for isothermal amplification starting from RNA (TMA, NASBA, SPIA), 81 
whereas others initially targeted DNA (SDA, LAMP, HDA, RPA, RCA) and were only 82 
later adapted for RNA targets. Nonspecific intercalating fluorophores or fluorescent 83 
primers have been used for real time detection in LAMP, SDA, HDA and RCA, and 84 
specific detection probe formats have been developed for NASBA, RCA, HDA and 85 
RPA (24, 28, 31, 37, 38).  86 
In isothermal and exponential recombinase polymerase amplification (RPA) the 87 
phage recombinase UvsX and its co-factor UvsY form a nucleoprotein complex with 88 
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oligonucleotide primers to scan for homologous sequences in a DNA template. 89 
Recognition of a specific homologous sequence leads to the initiation of strand 90 
invasion of the complex and the opposing oligonucleotides are then extended by 91 
isothermal (42°C) strand displacement amplification via Sau polymerase 92 
(Staphylococcus aureus) yielding dsDNA amplificates very much like in PCR. Real 93 
time amplificate detection can be performed by using TwistAmpTM exo-probes. Exo-94 
probes carry internal fluorophore and quencher linked to thymine bases and 95 
separated by an abasic site mimic (tetrahydrofuran) localized approximately 15 96 
nucleotides upstream from the 3’end of the probe (45-55 nucleotides (nt)). Once the 97 
probe hybridizes to its target sequence the abasic site is recognized and cleaved by 98 
Exonuclease III. The smaller downstream probe section carrying the quencher is 99 
released and fluorescence develops proportionally to the RPA mediated amplification 100 
(31).  101 
The second probe type for real time fluorescent detection is the TwistAmpTM fpg 102 
probe, a 30nt oligonucleotide, which carries a quencher at the 5’end and the 103 
fluorophore at an internal position 4-5nt downstream from the quencher via a C-O-C 104 
linker (or dR group). During hybridisation of the probe the linker is cleaved by the 105 
DNA glycosylase FPG (E. coli), thus causing separation of flurophore and quencher 106 
and subsequently the proportional increase of fluorescence. 107 
The purpose of the study to develop a panel of RPA assays for a POC microfluidic 108 
platform. We describe the development of highly sensitive and specific fluorescent 109 
real time RPA and RT-RPA assays for the detection of relevant Category A 110 
Bioterrorism Agents including gram+, gram- bacteria, and DNA and RNA viruses on 111 
the mobile ESEquant Tubescanner device. This mobile small footprint device collects 112 
fluorescence signals over time allowing for simultaneous real time documentation of 113 




Materials and Methods 116 
Quantitative molecular standards 117 
Bacteria: Quantitative pCRII backbone plasmid standards were generated for the 118 
pagA gene (Bacillus anthracis plasmid pX01), pla gene (Yersinia pestis) as described 119 
in (40). A capC gene carrying plasmid (B.anthracis, plasmid pX02) was provided by 120 
the Robert-Koch-Institut (7). DNA virus: The Variola virus (VARV) HA gene was 121 
synthesized and ligated into pMA-RQ by Geneart, Regensburg, Germany, the 122 
Vaccinia virus (VACV) plasmid carrying the LE gene was provided by the Robert-123 
Koch-Institut (19). RNA Viruses: A quantitative Ebola virus (EBOV), Sudan virus 124 
(SUDV), Marburg virus (MARV) NP-gene RNA standards were used as described 125 
(41, 43). A new quantitative Sigma virus (SIGV) G gene based RNA standard was 126 
generated and transcribed as described (43). 127 
 128 
Viral and bacterial material 129 
Genomic DNA of Orthopox viruses (Vaccinia virus (Elstree 5), Camelpox virus 130 
(CP19), Monkeypox virus (MP4) and Orthopox virus (OPV 90/3) was provided by 131 
Hermann Meyer, Institute of Microbiology, German Armed Forces. Inactivated and 132 
gamma-irradiated bacteria and viruses were provided by the following institutes: B. 133 
anthracis spores (ATCC 14578), Y. pestis (03-1501) and F. tularensis (Ft 12) by 134 
Centre for Biosecurity 2, Robert Koch Institute, Berlin; Vaccinia virus NYCBH strain 135 
(VR-1536), and Rift Valley fever virus (ZH548) by Centre for Biosecurity 1, Robert 136 
Koch Institute, Berlin; Marburg virus (Musoke strain) and Ebola virus (Zaire strain) by 137 
Bernhard-Nocht Institute, Hamburg; and Sigma virus by Institute of Virology, 138 
Göttingen. The organisms were cultured in the donating institutions at biosafety 3 or 139 
4 levels. 140 
 141 
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Real time PCR 142 
The quantitative standards for B. anthracis, capC and pagA, Y. pestis pla, F. 143 
tularensis tul4, VACV, RVFV, EBOV, SUDV and MARV were tested using published 144 
real time PCR protocols (19, 41, 43). A new real time PCR amplicon was designed 145 
for the SIGV G gene and for the VARV HA gene. Real time PCR assays for DNA and 146 
RNA targets were performed using the LightCycler® Fast-Start DNA Master 147 
HybProbe kit and the LightCycler® 480 RNA Master Hydrolysis Probes respectively 148 
on a Light Cycler 2.0 (Roche, Mannheim, Germany) using the 2nd derivative method 149 
for analysis. All real time PCR assays showed the sensitivities reported in the original 150 
publications. The SIGV and the VARV assays showed analytical sensitivities of 10 151 
molecules detected per reaction. 152 
 153 
RPA-conditions  154 
RPA was performed in a 50µl volume using the TwistAmp™ exo kit (TwistDX, 155 
Cambridge, UK) 420nM RPA primers and 120nM RPA-probe, 14mM Mg acetate and 156 
TwistAmpTM rehydration buffer. All reagents except for the template or sample DNA 157 
and Mg-acetate were prepared in a mastermix, which was distributed into 0.2 ml 158 
reaction tubes each containing a dried enzyme pellet. Mg–acetate was pipetted into 159 
the tube lids. Subsequently 1µl standard DNA or genomic DNA was added to the 160 
tubes. The lids were closed and the Mg-acetate centrifuged into the tubes using a 161 
minispin centrifuge and the tubes were immediately placed into a ESEquant 162 
tubescanner device (Qiagen Lake Constance, Stockach, Germany).  163 
For RT-RPA 10U Transcriptor (Roche, Mannheim, Germany), 20U RNaseOut, 2mM 164 
DTT and 22.4 mM Mg acetate were added to the DNA-RPA mix described above. 165 
The same amount of primers and TwistAmpTM fpg probe were used with the 166 
rehydration buffer and the enzyme pellets of the TwistAmpTM fpg kit. Subsequently 167 
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1µl cDNA was added to the tubes. Fluorescence measurements (Excitation 470nm, 168 
Detection 520nm (FAM channel)) were performed at 42°C for 20 minutes. This 169 
reaction temperature was determined as optimal in terms of sensitivity from a 170 
temperature range of 39°C to 42°C. The Tubescanner software permits evaluation of 171 
the increase of fluorescence above three standard deviations over the background 172 
determined in minute one (adaptable) i.e. threshold validation. Additionally the slope 173 
of the curve as mV/time can be used (slope adaptable) i.e. slope validation. For 174 
confirmation the calculation of the 2nd derivative of the turning point of the upward 175 
fluorescence development can be applied to individual fluorescence curves with a 176 
very low slope (15, 33). 177 
 178 
Determination of sensitivity and specificity  179 
All quantitative DNA and RNA standards were tested by RPA in 8 replicates, the 180 
threshold time (in minutes) was plotted against molecules detected and a semi-log 181 
regression was calculated. For exact determination probit regression (35) was 182 
performed and the sensitivity at 95% calculated using the Statistica software 183 
(StatSoft, Hamburg, Germany). 184 
In order to assay the sensitivity of extraction and detection in samples containing 185 
representative whole organisms of each category in the panel, inactivated, B. 186 
anthracis spores (gram positive), Y. pestis (gram negative), VACV (DNA virus), and 187 
RVFV (RNA virus) were diluted in 10-fold steps in PBS and spiked into plasma to 188 
achieve a final concentration of 101 - 104 genomic copies / ml. Additionally, 2 μl of 189 
Sigma virus in a concentration of 105 genome genomic copies / ml were added to the 190 
prepared spiked plasma dilutions to monitor the performance of the extraction 191 
procedure. 192 
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Total nucleic acids from all bacterial and viral pathogens were prepared spiked 193 
plasma samples using the single innuPREP MP Basic Kit A (Jena Analytik, Jena, 194 
Germany) a magnetic bead separation rack combined with proteinase K treatment 195 
according to the manufacturer´s instructions. The nucleic acids were eluted in 100µl 196 




Amplicon design 201 
The design of the RPA primers differs from PCR primers, as the minimum length of 202 
30-35 nt rather than the TM guides design. Since it is not clear which features of the 203 
5-prime end sequence of the primer actually supports the initiation of strand invasion 204 
typically several primer pairs have to be tested. On average 3 and at maximum 8 205 
primer pairs were tested and the final amplicon lengths in general ranged from 107nt 206 
to 164nt (table 1). Due to the high homology among the Orthopoxvirus sequences 207 
the most challenging design was that for VARV.  In the final design the RPA probe 208 
overlaps the upstream primer sequences by four nucleotides and covers a gap in the 209 
Variola sequence, which is not present in the other Orthopoxvirus sequences. 210 
Additionally the downstream primer mismatched all other Orthopoxvirus sequences 211 
at position 3 down from the 3-prime end to specifically select for the VARV 212 
sequences according to the ARMS principle (27). A RPA assay for VACV was 213 
designed for the same region for use in the extraction experiments. 214 
 215 
Assay development steps for RT-RPA 216 
The detailed development of DNA-RPA and RT-RPA was described for the assays  217 
for F. tularensis assay and RVFV respectively elsewhere (9, 10).  218 
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We here additionally describe comparison of the performance of the fluorescent 219 
TwistAmpTM exo-probe and the TwistAmpTM fpg probe in RT-RPA. We designed exo- 220 
and fpg-probes for the same target regions for EBOV, MARV and SIGV and tested 221 
them on the respective quantitative RNA standards. The sensitivities for the 222 
TwistAmpTM fpg probe assays were respectively 3-, 6-, and 3-log10-steps lower than 223 
the sensitivities of the TwistAmpTM exo-probe assays. The results for EBOV are 224 
shown in Fig 2A. 225 
 226 
RPA sensitivity 227 
Quantitative molecular plasmid and RNA standards were generated and verified by 228 
real time PCR (data not shown) and used to test the analytical sensitivity of all final 229 
RPA assays (Figure 3AB, table 3). The analytical sensitivity of the DNA-RPA assays 230 
was about 10 molecules detected (md) or as per probit analysis 16-19 md per 231 
reaction. Only the assay for the capC gene of B. anthracis plasmid pX02 showed a 232 
lower sensitivity of 100-1000 md or as per probit analysis 778 md per reaction 233 
(Figure 3A, Table 3). The standard deviation of the standard curve threshold time 234 
values ranged from 0.1 at 107 molecules to 2.6 at 10 md. The slopes of the semi-log 235 
standard regression lines (SRL) ranged from -0.33 to -0.96 indicating an efficiency of 236 
1072 to 11 if using the formula E=101/slope used for real time PCR assays which at an 237 
idealised exponential efficiency have an efficiency of 1.  238 
RT-RPA was performed, by adding Transcriptor RT enzyme (Roche, Mannheim) to 239 
the RPA mix. Optimal performance was observed at 22.4mM Mg acetate and 240 
2mMDTT and the analytical sensitivities of the RPA assays ranged from 10-100 md 241 
or as per probit analysis from 16-21 md per reaction (Figure 3B, Table 3). The 242 
standard deviation of the standard curve threshold time values ranged from 0.2 at 107 243 
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molecules to 2.6 at 10 md. SRL slopes ranged from 0.9 x10-6 to 0.56 indicating an 244 
efficiency (E=101/slope) of 108 to 61.  245 
 246 
Sensitivity of RPA assays in whole organism nucleic acid extracts 247 
Extraction efficiency of the innuPREP MP basic kit was tested with plasma spiked 248 
with whole organisms of each organism category encountered in the biothreat panel 249 
using real time PCR assays. Results of the performance of the innuPREP MP basic 250 
kit tested by real time PCR analysis are illustrated in Fig. 4. Pathogens spiked in 251 
plasma at a range of 104-101 md per reaction were efficiently extracted by the 252 
innuPREP MP basic kit and were detected at high sensitivity by real-time PCR 253 
methods. Additionally, the internal control was efficiently detected in extracts of all 254 
the spiked samples as determined by real time PCR (CT 22.56 ± 0.51, n= 64). The 255 
results here demonstrate that this total nucleic acid extraction method is robust and 256 
highly reproducible. The same extracts were used for detection by the respective 257 
RPA assays. The results of RPA performance are summarized in table 4. The (RT)-258 
RPA assays for F. tularensis and RVFV each specifically detected strains of 259 
respective strain panels as described in (9, 10). 260 
 261 
Specificity  262 
The specificity of all RPA assays was determined by cross testing human genome 263 
DNA, and the nucleic acids of all the other biothreat agents in the panel i.e. genomic 264 
DNA of Y. pestis (strain 03-1501), F. tularensis ssp. holarctica (strain LVS), B. 265 
anthracis (strain 3007), Vaccinia virus (VR-1536), the VARV plasmid, the genomic 266 
RNA of Ebola virus, Sudan virus, Marburg virus and Sigma virus. Only specific 267 
detection was observed. Additionally the RPA assay for VARV did not detect the 268 
genomic DNA of tested Orthopox viruses. These were all detected by the VACV RPA 269 
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assay, which did not detect the VARV plasmid. The RPA assays for the detection of 270 
bacteria were tested against a panel of bacterial genomes as described earlier (Table 271 
1 in (9), table S1) and showed exclusively specific detection. 272 
To assay the influence of human genomic DNA on the RPA assays, we determined 273 
the concentration of human DNA in the eluates of negative sera extracted with the 274 
RNeasy kit (Qiagen). We then added the determined average amount of 70 ng/µl 275 
human genomic DNA to RPA and RT-RPA reactions. The added background DNA 276 
delayed threshold time points negligibly for RPA and up to 3 min for one-step-RT-277 
RPA. It had no effect on the sensitivity (Fig. 2 B, C). 278 
 279 
5. Discussion 280 
 281 
In order to develop a panel of isothermal detection assays for Category A 282 
Bioterrorism Agents we assessed recombinase polymerase amplification (RPA) for 283 
the following reasons: (i) it is an exponential amplification with specific amplificate 284 
confirmation using a fluorescent probe, (ii) it contains GP32, a single strand binding 285 
protein and a good enhancer for the amplification of RNA molecules with complicated 286 
secondary structures (42), (iii) it needs only three conserved regions for 287 
olignucleotide design, (iv) available dried pellet reagents facilitate field use or point of 288 
care applications.  289 
As to analytical sensitivity and specificity, the RPA assays developed showed a 290 
performance equal to PCR (table 3) and showed no cross detection amongst their 291 
respective targets. Compared to PCR, RPA reaction time however was much shorter 292 
and surprisingly one-step-RT-RPA assays were quicker (LOD reached at 4-8 293 
minutes) than RPA assays (LOD reached 7 -10 minutes).  294 
The SRLs of the RT-RPA assays showed even lower slope values indicating very 295 
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fast reaction kinetics. We assume that this might be due to an additive effect of the 296 
fluorogenic detection of (i) RNA templates, (ii) the initially generated cDNA (ssDNA) 297 
as is generic in T7 promotor driven isothermal assays such as TMA or NASBA, and 298 
(iii) the RPA products (dsDNA). Alternatively the initiation of RPA may be facilitated 299 
by single stranded cDNA. 300 
The published Km values for Exonuclease III (Km= 6.3 x 10
-9 M (nicks/minute), (18), 301 
and FPG (Km= 7 x 10
-9 M (excisions/min), (4)) range in the same order of magnitude 302 
implying comparable activity levels. Nevertheless, the assays using cleavage of fpg-303 
probes showed a significantly reduced sensitivity than the exo-probe assays (Fig. 304 
2A), suggesting that in RPA the FPG enzyme kinetics are not as favourable to real 305 
time detection as those of Exonuclease III. 306 
The results of the whole organism extraction experiments indicate that the magnetic 307 
bead based total nucleic acid extraction kit used showed efficient extraction of DNA 308 
and RNA for all tested organism categories. Moreover, it was demonstrated that real 309 
time PCR and RPA show comparable detection sensitivities when in these extracts 310 
(table 4). 311 
LAMP assays may also be considered as a good option for isothermal detection and 312 
miniaturisation (2). In general LAMP assays need 4-6 primers leading to longer 313 
amplicons and possibly more difficult design in the case of highly variable RNA 314 
viruses, whereas the RPA design with three oligonucleotides offers almost the same 315 
flexibility as real time PCR. However the longer TwistAmpTM exo-probes can be a 316 
design obstacle, which can be partly circumvented by allowing probe and primer to 317 
overlap. The use of LNA nucleotides might help to reduce probe length as has been 318 
shown for TaqMan probes (11, 39).  319 
In comparison published LAMP assays for B. anthracis, Monkeypox, RVFV, MARV 320 
and EBOV (table 3) have longer run times (18 – 60 minutes) at 60-63°C than the 321 
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RPA assays but show about the same sensitivity (Table 3). However, not all LAMP 322 
assays have been adapted for real time fluorescence as some of them use turbidity 323 
index for readout. 324 
The current advantage of RPA is that the reaction mixture containing enzymes, 325 
nucleotides and buffer are provided in dried pellets, which is very well amenable to 326 
POC or field use. This is now also possible for RT-RPA (10). The only ingredients 327 
that need to be added are primers, probe and sample. 328 
With a small footprint of 17.4 x 18.8 cm and a weight of 1kg (including the labptop) 329 
the ESEquant tubescanner system is significantler lighter and smaller than all other 330 
available state of the art mobile PCR cyclers such as SmartCycler, R.A.P.I.D., 331 
RAZOR (5-35kg), or the Loopamp® Realtime Turbidimeter 2.0 for LAMP assays 332 
(5kg). At 4000 Euro the ESEquant tubescanner is also considerably cheaper than 333 
any of the mobile PCR devices. In combination with the ESEquant tubescanner RPA 334 
is therefore a very attractive nucleic acid detection method that could easily be 335 
installed in hospitals or laboratories, which cannot afford real time PCR cyclers.  336 
The only constraints of isothermal amplification methods are enzyme activity rates 337 
since there is no dependency on rapid temperature ramping as in PCR. This feature 338 
makes them more amenable to engineer microfluidic lab-on-chip devices than PCR. 339 
A recent review on miniaturisation efforts for NASBA, LAMP, HDA, SDA, RCA and 340 
RPA pointed out that low temperature isothermal methods such as SDA, NASBA, 341 
RCA and RPA show an advantage for minaturisation as they need much less energy 342 
input and are therefore better candidates for battery driven handheld devices than 343 
high temperature isothermal reactions (LAMP, SmartAmp, HDA) (2). 344 
The implementation of RPA on centrifugational LabDisks was recently described 345 
(25). This type of cartridge could fullfill to the requirements for simple benchtop 346 
devices if sample preparation were included. It would come closest to a lab on a 347 
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cartridge in contrast to the majority of systems for miniaturized molecular assays 348 
currently developed which have aptly been described as ‘chip in lab’ rather than ‘lab 349 
on chip’ platforms (2). 350 
In summary we have developed a panel of very rapid and highly sensitive isothermal 351 
real time RPA assays for the detection of Category A Bioterrorism Agents covering 352 
gram negative, gram positive bacteria, DNA viruses and RNA viruses. We also 353 
showed that a commercially available magnetic bead based total nucleic extraction 354 
kit, which could be used in resource-poor settings can be efficiently combined with 355 
RPA. We now aim at integrating all assays onto a microfluidic POC device and 356 
testing this syndromic panel of RPA assays on clinical samples. 357 
 358 
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Figure Legends 509 
 510 
Figure 1. Details of the RPA amplicon for VARV. All nucleotides in the alignment 511 
matching in the VARV sequence are presented as dots. Primer sequences are 512 
presented as full sequences. Gaps are presented as hyphens. VARV RPA FP is 513 
presented in sense and VARV RPA P and RP are presented as reverse complement 514 
sequences. Grey fields: VARF RPA FP: Degenerated IUB code positions, VARV 515 
RPA P: The TTT triplet used for the attachment of BTF (table 2), VARF RPA RP: 516 
nucleotide at positon 3 of the 3-prime end mismatching all other orthopoxviruses. 517 
Sequences: cowpox AY902252, camelpox AF438165, monkeypox AF380138, 518 
vaccinia virus M35027, variola virus X69198. 519 
 520 
Figure 2. Real time (RT-)RPA assay performance. A: Comparison of exo-probe and 521 
fpg-probe performance in RT-RPA. Standard regression lines (SRLs) for EBOV one-522 
step-RT-RPA were generated from eight data sets (exo-probe, black squares) and 3 523 
data sets (fpg-probe, white squares). B: Influence of background DNA on EBOV one-524 
step-RT-RPA, black squares: SRL as above, white squares: SRL of the same assay 525 
with 70ng human genome DNA background. C: Influence of background DNA on 526 
RPA, black squares: SRL derived of 8 data sets of B. anthracis RPA, white squares: 527 
SRL of the same assay with 70ng human genome DNA background. 528 
 529 
Figure 3. Standard regression lines (SRL) of all developed assays including assays 530 
for Francisella tularensis and Rift Valley fever virus already decribed in (9, 10). SRLs 531 






Figure 4: 537 
Extraction efficiency of the innuPREP MP basic kit. Plasma was spiked with whole 538 
organisms (range: 10x -10x/ml) and nucleic acids were extracted. Eluates were tested 539 
by respective quantitative real time PCR assays in triplicate. The amount of 540 
measured md per reaction is plotted against the 10-fold serial dilution of pathogens in 541 
plasma. The dotted line represents calczulated 100% efficiency of extraction. A: B. 542 
anthracis (gram positive) extracts tested with pag-PCR, B: Y.pestis (gram negative) 543 
tested with pla-PCR, C Vaccinia virus tested with LE-PCR, D Marburg virus tested 544 




Table 1. Details of RPA amplicon design 548 
 549 









Sequences used in the design









B. anthracis pagA CP001216 
144299- 144424 




B. anthracis capC AF188935 
55735- 55885 





Variola virus HA X69168 
151606- 151732 
126nt X69168, Y16780, DQ441416, 
DQ441418-48, DQ437500, 
DQ437581-91 
Vaccinia virus HA DQ121394 
165441- 165584 
143nt M35027, U94848, AY243312, 
AY313847-48, AY603355, 
NC_006998, DQ121394 
Ebola virus NP AY142960 
1779-1943 
164nt Jo44337, L11365, AF086833, 
AY142960, AF499101, 
AF272001, EU22440, 
AY354458, Y09358, AY054908, 
AY058895, EU051640-50 
Sudan virus NP AF173836 
1783- 1868 
130nt AF173836, AY729654, 
NC_006432, EU338380 
Marburg virus NP FJ750959 
1121 - 1256 
135nt Z12132, Z29337, NC_0016081, 
DQ217792, AY430365-66, 
X68495, M72714, DQ447649-
61, AY358025, FJ750953-59 
Marburg virus NP FJ750953 
1121 - 1260 
107nt 










RPA primers and exo-probes 
 
DNA assays 
BA1 RPA FP TACAGGGGATTTATCTATTCCTAGTTCTGAG 
BA1 RPA RP GTAGCAAATGTATATTCATCACTCTTCTTAAC 
BA1 RPA P GAAAATATTCCATCGGAAAACCAATATTTTCA-BTF-GCTATTTGGTCAGGAT-P 
BA2 RPA FP CTGGAACAATAACTCCAATACCACGGAATTCA 
BA2 RPA RP GGTGTTTCAAGATTCATGATTTTATATGGCCG 
BA2 RPA P TGGCATAACAGGATAACAATAATCAAATAAAAGT-BTF-AAACAAATACCTGTAATTAGC-P 
YP RPA FP CCAGTATCGCATTAATGATTTTGAGTTAAATGC 
YP RPA RP TCCAGCGTTAATTACGGTACCATAATAACGTGAG 
YP RPA P CGACTGGGTTCGGGCACATGATAATGATGAGCACTA-BTF-GAGAGATCTTACTT-P 
VARV RPA FP GAGAATCCACAACMGACAAGACKTCSGGAC 
VARV RPA RP TTGGCGGTTGATTTAGTAGTGACAATTTCA 
VARV RPA P TGTATGAGACAGTGTCTGTGACTGTATGA-BTF-TCTTTATTAGTAATTGGTCC-P 
VACV RPA FP ACATACACTAGTGATAGCATTAATACAGTAAG 
VACV RPA RP AGATGATGTACTTACTGTAGTGTATGAGACAGT 
VACV RPA P TCTTCTTATCAGTAATTGGTTCCGGAGTCTCG-BTF-TGTGGATTCTCCA-P 
  
RNA assays 
EBO RPA FP GACGACAATCCTGGCCATCAAGATGATGATCC 
EBO RPA RP CGTCCTCGTCTAGATCGAATAGGACCAAGTC 
EBO RPA P GATGATGGAAGCTACGGCGAATACCAGAG-BTF-CGGAAAACGGCATG-P 
SUD RPA FP CAACTATYCCAGGTGGTGTTGTTGACCCGT 
SUD RPA RP GGCTGTCRTCATCGTCGTCGTCCAAATTGAAGA 
SUD RPA P CTCCTGTGGTGCCTTCAGCCGAATCCTCG-BTF-CAGGATAATTATTACT-P 
MAR1 RPA FP CATGAACATCAGGAAATTCAAGCTATTGCMGARG 
MAR1 RPA RP CTAATTTTTCTCGTTTCTGGCTGAGGACGGC 
MAR1 RPA P TGTGTGTGATTTCAGTTTTYTGAAGGTGGAAY-BTF-TCTAATATCTTCC-P 
MAR2 RPA FP CGACATGAACACCAGGAAATTCAGGCCATCGCC 
MAR2 RPA RP CGAGCTAGTTTCTCTCGTTTCTGGCTGAGGAC 
MAR2 RPA P AATCTCAGTCTTCTGGAGATGGAACTGTTCTAA-BTF-TTTTCTCTCTTCGTC-P 
SIGV RPA FP TGACCATCCTAACTCTGTGACATTCCAAGT 
SIGV RPA RP GTTGACAGTGAGCTCTTGAATCTCTGGGTT 
SIGV RPA P ACTGATTTCCCTCCGTGTCCTCCCGGTACCAC-BTF-CCAAACTGCCGTTGTG-P 
MARV FPG P (dR-FAM)GCCGT-B-CTCAGCCAGAAACGAGARAAAYTAGC(C3-Spacer) 
ZEBO FPG P (dR-FAM)GGCG-B-ATACCAGAGTTACTCGGAAAACGGCATGAA-P 
SIG FPG P (dR-FAM)TGTC-B-TCCCGGTACCACTATCCAAACTGCCGTTGT-P 
 554 
FP / RP: forward and reverse primer, P probe, BTF: B: thymidine nucleotide carrying 555 
Blackhole quencher 1, T: tetrahydrofuran spacer, F: thymidine nucleotide carrying 556 





















RPA threshold  





DNA assays      
B. anthracis (pagA) 101 - 102   (7) 101 - 102  16 8 103 (21) 
B. anthracis (capC) 102 - 103  (7) 102 - 103  778 7 103 (21) 
F. tularensis (tul4) 102 * (8) 101 - 102  (9) 19 10 n.d.  
Y. pestis (pla) 2*  (26) 101 - 102  16 8 n.d.  
Variola virus 101 - 102  (32) 101 - 102  16 10 102  (16) 
 
RNA assays 
     
Rift Valley fever virus (N) 102 101 - 102  (10) 19 7 102 (23, 30) 
Ebola virus (NP) 102 101 - 102  21 7 101  (22) 
Sudan virus (NP) 101 101 - 102  17 8 n.d.  
Marburg virus (NP) 101 101 - 102  21 8 102  (20) 
Sigma virus (G) 101 
 
101 - 102  16 4 n.d.  
 563 
 564 







Table 4 Comparison of assay sensitivity in nuclear extracts 571 
 572 
Infectious agent Real time PCR  
sensitivity in extracts 
(molecules detected)
Real time RPA  
sensitivity in extracts  
(molecules detected) 
B. anthracis* (gram+) 10 10 
Y. pestis (gram-) 10 10 
Vaccinia virus (DNA virus) 10 10 
RVFV (RNA virus) 100 100 
SIGV (RNA virus IPC) 100 1000 
 573 
• pagA assays used for detection 574 
 575 
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 577 

A Figure 2
B
C
A
Figure 3
B
Figure 4
A B
C D
